Paul brings to Pairidex over 20 years of executive leadership experience across the biotech and clinical industries, with a proven track record of driving innovation, scaling organizations, and building high-performing teams. Most recently, he served as CEO at NX Prenatal.

Pairidex continues to grow and evolve in developing droplet digital PCR assays designed to enable accurate detection of gene fusions in blood cancer.

Our CAP-CLIA-Certified laboratory offers a sensitive assay with rapid turnaround and reduced costs, enabling more accurate disease monitoring and treatment analysis providing absolute oncogenic fusion quantification – down to 1 in 100,000 fusion transcripts – while maintaining an exceptionally low false-positive rate.

Paul’s vision and leadership will be instrumental in shaping our next chapter. We are confident that under his guidance, Pairidex will continue to accelerate progress and deliver exceptional value to our customers, partners, and stakeholders.